Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with Comirnaty®: a randomized, observer-blind, controlled, phase 1 study.
Similar reactogenicity and immunogenicity profiles of ZR-202-CoV, ZR-202a-CoV and Comirnaty<sup>Ⓡ</sup> support further clinical investigation in a wider population.
Authors
- Fatoumata Diallo (ORCID: https://orcid.org/0000-0002-1423-3417)
- Silvia Grappi
- Chenliang Zhou (ORCID: https://orcid.org/0000-0002-1918-3578)
- Min Ji (ORCID: https://orcid.org/0000-0002-4257-8113)
- Fadima Cheick Haidara (ORCID: https://orcid.org/0000-0003-1121-2941)
- Samba O. Sow (ORCID: https://orcid.org/0000-0002-6335-5066)
- Milagritos D. Tapia (ORCID: https://orcid.org/0000-0002-6476-3934)
- Martina Monti (ORCID: https://orcid.org/0000-0002-2173-7269)
- Simonetta Viviani (ORCID: https://orcid.org/0000-0002-3652-5082)
- Yuan Lin (ORCID: https://orcid.org/0000-0003-3091-9889)
- Qing Yang (ORCID: https://orcid.org/0000-0001-8623-7532)
- Lei Shi (ORCID: https://orcid.org/0000-0003-2543-0042)
- Han Xi
- Ge Liu
- Jingjing Chen (ORCID: https://orcid.org/0000-0002-1857-8498)
- Bang‐Wei Yu
- Yalin Hu
Institutions
- University of Siena (IT)
- University of Maryland, Baltimore (US)
- Centre Pour le Développement des Vaccins-Mali (ML)
- Shanghai CASB Biotechnology (China) (CN)
- VisMederi Research (IT)
- Yunnan Yingmao Biotechnology (China) (CN)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.ijid.2024.107237
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Coalition for Epidemic Preparedness Innovations